Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
Status:
Recruiting
Trial end date:
2022-12-27
Target enrollment:
Participant gender:
Summary
This is a First-In-Human (FIH) study of [68Ga]-FF58 to characterize the imaging properties,
safety, biodistribution and dosimetry properties of [68Ga]-FF58 in adults with relapsed or
refractory (r/r) glioblastoma multiforme (GBM) or Human Epidermal growth factor Receptor 2
positive (Her2+) breast cancer that has metastasized to the brain expected to overexpress
alpha-v beta 3 (αvβ3) and alpha-v beta 5 (αvβ5) integrins.